C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!

Pharma Press Releases

Keep up to date with the latest technological developments happening across the Pharmaceutical industry. Our press releases can help you boost your online reach and exposure worldwide. Our Press releases provides information on the latest research in pharma.

Recipharm and Moderna Finalize Agreement for Aseptic Drug Product Manufacturing and Fill-Finish for Supply to Countries Outside the U.S.

Wednesday, December 30, 2020

Moderna Inc biotechnology company pioneering messenger RNA mRNA therapeutics and vaccines and Recipharm STO RECIB a leading contract development and manufacturing organization CDMO

Centene Completes Acquisition of PANTHERx Rare Pharmacy (PANTHERx)

Wednesday, December 30, 2020

Centene Corporation today announced that it has completed its acquisition of PANTHERx one of the largest and fastestgrowing specialty pharmacies in the United States specializing in orphan drugs and treating rare diseases

Chi-Med Announces the NMPA Approval of Surufatinib (Sulanda® in China) for Non-Pancreatic Neuroendocrine Tumors

Wednesday, December 30, 2020

Hutchison China MediTech Limited ChiMed today announces that surufatinib has been granted approval for drug registration by the National Medical Products Administration of China NMPA for the treatment of nonpancreatic neuroendocrine tumors NETs Suruf...

Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B

Wednesday, December 30, 2020

Altimmune Inc a clinicalstage biopharmaceutical company today announced that it has enrolled the first patient in its multinational Phase clinical trial of HepTcell a novel peptidebased immunotherapeutic under development for treatment of chronic he...

Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung Disease

Thursday, December 31, 2020

Arcturus Therapeutics Holdings Inc a leading clinicalstage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases

Propanc Biopharma Advances POP1 Joint Research and Drug Discovery Program for Projected US$111.2B Global Metastatic Cancer Market

Thursday, December 31, 2020

Propanc Biopharma Inc a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer announced today that the Proenzymes Optimization Project POP joint research and drug discovery program a...

Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination, at an affordable price for adults with Type 2 Diabetes in India

Tuesday, December 29, 2020

Glenmark Pharmaceuticals Limited Glenmark a researchled global pharmaceutical company has launched a fixed dose combination FDC of its novel patent protected and globally researched Sodium Glucose CoTransporter Inhibitor SGLTi

Amphastar Announces Approval for Glucagon for Injection Kit, 1mg

Tuesday, December 29, 2020

Amphastar Pharmaceuticals Inc announced that the US Food and Drug Administration FDA has approved its Abbreviated New Drug Application ANDA for Glucagon for Injection Emergency Kit mg Glucagon is indicated for the treatment of severe hypoglycemia an...

Clovis Oncology Submits Investigational New Drug Applications for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial

Tuesday, December 29, 2020

Clovis Oncology Inc today announced that the company has completed submission of two Investigational New Drug IND applications to the US Food and Drug Administration FDA for FAP the lead compound in its peptidetargeted radionuclide therapy PTRT devel...

Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80 Million Patient Encounters in the U.S. Annually

Wednesday, December 30, 2020

Eyenovia Inc a clinical stage ophthalmic biopharmaceutical company with Phase programs in presbyopia myopia and mydriasis today announced that it has submitted a New Drug Application NDA to the U S Food and Drug Administration FDA for MydCombi a uni...